Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04216589 (A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- The effects of high-intensity interval training versus continuous moderate-intensity exercise on body composition among older adults with HIV.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Trial
- Semaglutide-Induced Sarcopenia via GLP-1R-mTOR-Satellite Cells Axis and Muscle-Glucose Feedback Loop Potentially Leading to Refractory Hyperglycemia in Type 2 Diabetes: A Case-Driven Hypothesis.Problemy endokrinologii · 2026Article
- Interventions and opportunities to enhance aging among people with HIV: a focus on frailty, sarcopenia, and intrinsic capacity.Topics in antiviral medicine · 2026Review
- GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity.Current nutrition reports · 2026Article
- 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Optimizing Weight Loss in the GLP-1 Era: Preserving Muscle Mass, Function and Metabolic Health Through Precision Nutrition and Resistance Training.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Pilot study of epigenetic aging and treatment response to semaglutide in the SLIM LIVER study.npj aging · 2026Article
- New Updates in Adipocytes and Adipose Tissue: 2nd Edition.Life (Basel, Switzerland) · 2026Article
- Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans.Cell reports. Medicine · 2026Article
- Liver disease in people living with HIV infection: a changing landscape.Nature reviews. Gastroenterology & hepatology · 2026Review
- 15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist-Induced Weight Loss.bioRxiv : the preprint server for biology · 2026Article
- Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments.Current HIV/AIDS reports · 2026Review
- Muscle health in the modern era of incretin-based therapies.European journal of clinical investigation · 2026Review
- Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review.Drugs · 2026Review
- Preserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy.Current cardiology reports · 2025Review
- Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions.Journal of cachexia, sarcopenia and muscle · 2025Article
- Impact of Incretin-Based Therapy on Skeletal Muscle Health.Medicina (Kaunas, Lithuania) · 2025Review
- Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSemaglutide is highly effective for decreasing weight. Concomitant loss of muscle mass often accompanies weight loss and may have consequences on muscle function.
methodsThis is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD). Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4). Psoas volume and fat fraction were assessed from liver magnetic resonance imaging, and physical function was assessed by 10-time chair rise test and 4 m gait speed. Mean change from baseline to week 24 was estimated with linear regression modeling.
resultsFifty-one PWH were enrolled (muscle measures n = 46). The mean age was 50 years (standard deviation, 11), body mass index was 35.5 kg/m2 (5.6), 43% were women, 33% Black, and 39% Hispanic/Latino. Psoas muscle volume decreased by 9.3% (95% confidence interval [CI]: -13.4 to -5.2; P < .001) over 24 weeks, but psoas muscle fat did not significantly change (-0.42%; 95% CI: -1.00 to .17; P = .16). Chair rise and gait speed showed nonsignificant improvements of 1.27 seconds (95% CI: -2.7 to .10) and 0.05 m/sec (95% CI: -.01 to .10), respectively (both P > .07). The prevalence of slow gait speed (<1 m/sec) decreased from 63% to 46% (P = .029).
conclusionsIn PWH receiving semaglutide for MASLD, despite decreased psoas muscle volume, there was no significant change in physical function, suggesting function was maintained despite significant loss of muscle. CLINICAL TRIALS REGISTRATION: NCT04216589.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.